Abstract:OBJECTIVE:To evaluate the role of 2-deoxy-D-glucose (2-DG) modified supermagnetic iron oxide nanoparticles (SPIO) (γ-Fe2O3@DMSA-DG NPs) in tumor detection as a magnetic resonance imaging (MRI) contrast agent.METHODS:γ-Fe2O3@DMSA-DG NPs was prepared. The degree of A549 cells targeted absorption of γ-Fe2O3@DMSA-DG NPs was detected by Prussian blue staining, colorimetric assay, T2W and multi-echo sequence MRI. γ-Fe2O3@DMSA NPs was used as a control agent, and free D-glucose as a competitive inhibitor. Human lung adenocarcinoma A549 xenograft tumor was prepared in nude mice. Sterile aqueous suspension of γ-Fe2O3@DMSA NPs or γ-Fe2O3@DMSA-DG NPs was injected into the tail vein of nude mice. Before and 6, 12, 24, 48 h after injection, MRI imaging of the mice was performed. T2 signal intensity of the tumor, brain, liver and thigh skeletal muscles, and T2 values of the tumors were measured.RESULTS:The average diameter of the particles was about 10 nm, and there were no significant differences between the diameters of γ-Fe2O3@DMSA NPs and γ- Fe2O3@DMSA-DG NPs. The IR spectra showed the C-N retractable vibration peak at γ-Fe2O3@DMSA-DG NPs surface, indicating that 2-DG was conjugated to the γ-Fe2O3@DMSA NPs. The Prussian blue staining, colorimetric assay, MRI T2 signal intensity and T2 values revealed that γ-Fe2O3@DMSA-DG NPs were significantly more absorbed by A549 cells at growth peak than γ-Fe2O3@DMSA NPs, and the absorption of γ-Fe2O3@DMSA-DG NP was inhibited by free D-glucose. The results of in vivo examination showed that before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA-DG NPs, the mean T2 signal intensities of the tumors were (326.00 ± 16.26)s, (276.40 ± 5.13)s, (268.40 ± 30.58)s, (240.40 ± 25.93)s, (262.20 ± 30.04)s, respectively, and the T2 values of the tumors were (735.80 ± 20.93) ms, (645.80 ± 69.58) ms, (615.00 ± 124.61) ms, (570.60 ± 67.78) ms, and (537.80 ± 105.29) ms, respectively. However, before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA NPs, the mean T2 signal intensities of the tumors were (335.60 ± 4.93)s, (290.80 ± 5.93)s, (273.40 ± 15.08)s, (327.40 ± 16.65)s, and (313.20 ± 20.45)s, respectively, and T2 values were (686.00 ± 21.44)ms, (617.80 ± 69.93)ms, (645.20 ± 85.89)ms, (669.40 ± 13.72)ms, and (608.80 ± 61.90)ms, respectively. The T2 signal intensity and T2 value of the tumors were not declined generally after injection. The liver T2 signal intensity was decreased after injection of both γ-Fe2O3@DMSA-DG NPs and γ-Fe2O3@DMSA NPs, and T2 signal intensity of the brain and muscle did not show significant changes.CONCLUSIONS:γ-Fe2O3@DMSA-DG NPs has an ability to target glucose receptors overexpressed in tumors, and may serve as a MRI contrast agent for tumor detection.

Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-g1ucose modified SPIOs

Preparation of a Glucose Receptor-Mediated Tumor Targeting 2-Dg-conjugated Superparamagnetic Iron Oxide Nanoparticles and Its in Vitro Experimental Study

Mri of High-Glucose Metabolism Tumors: A Study in Cells and Mice with 2-Dg-modified Superparamagnetic Iron Oxide Nanoparticles

Targeted Gsh-Exhausting And Hydroxyl Radical Self-Producing Manganese-Silica Nanomissiles For Mri Guided Ferroptotic Cancer Therapy

2-Deoxy-d-glucose Modified Supermagnetic Iron Oxide Nanoparticles Enhance the Contrasting Effect on MRI of Human Lung Adenocarcinoma A549 Tumor in Nude Mice

2-Deoxy-d-glucose Modified Magnetic Nanoparticles with Dual Functional Properties: Nanothermotherapy and Magnetic Resonance Imaging

Biotargeting rhabdomyosarcoma A-673 cell of 2-DG modifiedsuperparamagnetic iron oxide nanoparticles with different surface coating

Breast Cancer Diagnosed by MRI Using Mesoporous TiO₂-Coated (Fe₃O₄) Nanoparticles

Preparation, Characterization of 2-Deoxy-d-glucose Functionalized Dimercaptosuccinic Acid-Coated Maghemite Nanoparticles for Targeting Tumor Cells

Doxorubicin and indocyanine green loaded superparamagnetic iron oxide nanoparticles with PEGylated phospholipid coating for magnetic resonance with fluorescence imaging and chemotherapy of glioma

Nanoparticles of 2-Deoxy-d-glucose Functionalized Poly(ethylene Glycol)-Co-poly(trimethylene Carbonate) for Dual-Targeted Drug Delivery in Glioma Treatment

Erythrocyte Membrane-Camouflaged PCN-224 Nanocarriers Integrated with Platinum Nanoparticles and Glucose Oxidase for Enhanced Tumor Sonodynamic Therapy and Synergistic Starvation Therapy.

Targeted Dual-Contrast T1- and T2-weighted Magnetic Resonance Imaging of Tumors Using Multifunctional Gadolinium-Labeled Superparamagnetic Iron Oxide Nanoparticles

Magnetic Targeting Combined with Active Targeting of Dual-Ligand Iron Oxide Nanoprobes to Promote the Penetration Depth in Tumors for Effective Magnetic Resonance Imaging and Hyperthermia.

Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics

Fe-doped biodegradable dendritic mesoporous silica nanoparticles for starvation therapy and photothermal-enhanced cascade catalysis in tumor therapy

2-Deoxyglucose Conjugated Platinum (II) Complexes for Targeted Therapy: Design, Synthesis, and Antitumor Activity.

Sialic Acid-Engineered Mesoporous Polydopamine Nanoparticles Loaded with SPIO and Fe3+ As a Novel Theranostic Agent for T1/T2 Dual-Mode MRI-guided Combined Chemo-Photothermal Treatment of Hepatic Cancer

The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: a preliminary study

Dual-targeting and Excretable Ultrasmall SPIONs for T1-weighted Positive MR Imaging of Intracranial Glioblastoma Cells by Targeting the Lipoprotein Receptor-Related Protein

Development of Peptide Conjugated Superparamagnetic Iron Oxide (SPIO) Nanoparticles for Targeted MR Imaging and Therapy of Pancreatic Cancer